US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002

SHANGHAI, April 2 (Bernama-AsiaNet) —  On March 31, 2021, Jemincare Group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.
 
Preclinical data showed that JMB2002 can precisely occupy the key epitope of the receptor binding domain (RBD) on the S1 subunit of the SARS-CoV-2 with human angiotensin-converting enzyme II (hACE2) binding interface, and has strong binding and blocking activities to the spike glycoproteins of mutant viruses including the South African mutant (B.1.351), the UK mutant (B.1.1.7) and the Brazilian mutant (P.1) .

http://mrem.bernama.com/viewsm.php?idm=39730


administrator

Related Articles